We added the following clinical trials to Metastatic Trial Search for May 2025. To see all clinical trials, please visit Metastatic Trial Search.
ER/PR Positive Trials
HER2 Negative Trials
HER2 Positive Trials
- Patritumab Deruxtecan Antibody Drug Conjugate with Anti-HER2 Targeted Therapy for Advanced HER2+ Breast Cancer
- BAY2927088 Targeted Therapy for Advanced Breast Cancer with HER2 Mutations
- Multiple Anti-HER2 Targeted Therapies for de Novo Metastatic HER2+ Breast Cancer
Triple Negative Trials
- TCR T Cell Therapy for Women with Advanced Triple Negative, HLA-A2+ Breast Cancer That Overexpresses NY-ESO-1
- Studying HLA Gene Changes and Storing Immune Cells for Future Immmunotherapy for Advanced Triple Negative Breast Cancer
- Invikafusp Alfa Immunotherapy with ADC for Advanced Triple Negative or HR+, HER2- Breast Cancer
- Sacituzumab Tirumotecan ADC With and Without Immunotherapy for Advanced Triple Negative Breast Cancer
- PYX-201 Antibody Drug Conjugate for Advanced Triple Negative and HR+, HER2- Breast Cancer
Other Stage IV Trials
- PET Scan to Predict Response to Immunotherapy for People with Metastatic Breast Cancer with Brain Metastases
- Coaching Program to Reduce Stress and Promote Resilience for People with Metastatic Breast Cancer
- Understanding the Experience of People with Advanced Breast Cancer Receiving Hospice Care
- ATX-295 Targeted Therapy for Advanced Breast Cancer
Last Modified on May 1, 2025